Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen

Barbara J. Turner, Daozhi Zhang, Christine Laine, Roger J. Pomerantz, Leon Cosler, Walter W. Hauck

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: We explored the effect of patient and provider factors on the type of antiretroviral regimen among women receiving therapy. Patients: Five hundred ninety-five New York State nonpregnant HIV + women with full Medicaid eligibility and at least 1 month of a prescribed antiretroviral regimen in federal fiscal years (FFY) 1997-1998 and intervals in FFY 1997-1998, who had delivered a liveborn baby within 5 years. Measurements: From pharmacy claims in 4 6-month intervals in FFY 1997-1998, data were extracted on (1) an acceptable ≥2 antiretroviral combination regimen per expert guidelines; and (2) a highly active regimen, including a protease inhibitor or nonnucleoside analog (highly active antiretroviral therapy [HAART]). Results: Of 1514 woman-6-month intervals with filled antiretroviral prescriptions, 82% had an acceptable regimen, and of 1246 woman-6-month intervals on acceptable antiretroviral therapy, half demonstrated the use of HAART. Adjusted odds ratios (AORs) of acceptable antiretroviral therapy were higher (p < .05) for HIV specialty care (AOR = 1.71 for one or two visits; AOR = 2.10 for 3+ visits) or HIV clinical trials site care (AOR = 1.43; 95% confidence interval [CI]: 1.01, 2.04). Among women on acceptable antiretroviral regimens, those aged older than 25 years (AOR = 1.69; CI: 1.13, 2.53) or who were high school graduates (AOR = 1.50; CI: 1.09, 2.06) had higher odds of HAART. Methadone-treated women had twofold and nearly three-fold higher AORs of acceptable antiretroviral regimens and HAART, respectively, than current drug users. Conclusion: Provider HIV expertise is associated with receipt of an acceptable antiretroviral regimen in women, although receipt of HAART is affected more by age, education, and current drug abuse. Methadone treatment seems to improve access to acceptable antiretroviral regimens as well as to HAART.

Original languageEnglish (US)
Pages (from-to)20-29
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume27
Issue number1
StatePublished - May 1 2001
Externally publishedYes

Fingerprint

Highly Active Antiretroviral Therapy
Odds Ratio
HIV
Methadone
Confidence Intervals
Therapeutics
Medicaid
Drug Users
Protease Inhibitors
Substance-Related Disorders
Prescriptions
Clinical Trials
Guidelines
Education

Keywords

  • Antiretroviral agents
  • Physicians' practice patterns
  • Practice guidelines
  • Quality of health care
  • Substance abuse

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Turner, B. J., Zhang, D., Laine, C., Pomerantz, R. J., Cosler, L., & Hauck, W. W. (2001). Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. Journal of Acquired Immune Deficiency Syndromes, 27(1), 20-29.

Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. / Turner, Barbara J.; Zhang, Daozhi; Laine, Christine; Pomerantz, Roger J.; Cosler, Leon; Hauck, Walter W.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 27, No. 1, 01.05.2001, p. 20-29.

Research output: Contribution to journalArticle

Turner, BJ, Zhang, D, Laine, C, Pomerantz, RJ, Cosler, L & Hauck, WW 2001, 'Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen', Journal of Acquired Immune Deficiency Syndromes, vol. 27, no. 1, pp. 20-29.
Turner, Barbara J. ; Zhang, Daozhi ; Laine, Christine ; Pomerantz, Roger J. ; Cosler, Leon ; Hauck, Walter W. / Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen. In: Journal of Acquired Immune Deficiency Syndromes. 2001 ; Vol. 27, No. 1. pp. 20-29.
@article{4ed4ece07d6e43528537fd501d769b7c,
title = "Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen",
abstract = "Objective: We explored the effect of patient and provider factors on the type of antiretroviral regimen among women receiving therapy. Patients: Five hundred ninety-five New York State nonpregnant HIV + women with full Medicaid eligibility and at least 1 month of a prescribed antiretroviral regimen in federal fiscal years (FFY) 1997-1998 and intervals in FFY 1997-1998, who had delivered a liveborn baby within 5 years. Measurements: From pharmacy claims in 4 6-month intervals in FFY 1997-1998, data were extracted on (1) an acceptable ≥2 antiretroviral combination regimen per expert guidelines; and (2) a highly active regimen, including a protease inhibitor or nonnucleoside analog (highly active antiretroviral therapy [HAART]). Results: Of 1514 woman-6-month intervals with filled antiretroviral prescriptions, 82{\%} had an acceptable regimen, and of 1246 woman-6-month intervals on acceptable antiretroviral therapy, half demonstrated the use of HAART. Adjusted odds ratios (AORs) of acceptable antiretroviral therapy were higher (p < .05) for HIV specialty care (AOR = 1.71 for one or two visits; AOR = 2.10 for 3+ visits) or HIV clinical trials site care (AOR = 1.43; 95{\%} confidence interval [CI]: 1.01, 2.04). Among women on acceptable antiretroviral regimens, those aged older than 25 years (AOR = 1.69; CI: 1.13, 2.53) or who were high school graduates (AOR = 1.50; CI: 1.09, 2.06) had higher odds of HAART. Methadone-treated women had twofold and nearly three-fold higher AORs of acceptable antiretroviral regimens and HAART, respectively, than current drug users. Conclusion: Provider HIV expertise is associated with receipt of an acceptable antiretroviral regimen in women, although receipt of HAART is affected more by age, education, and current drug abuse. Methadone treatment seems to improve access to acceptable antiretroviral regimens as well as to HAART.",
keywords = "Antiretroviral agents, Physicians' practice patterns, Practice guidelines, Quality of health care, Substance abuse",
author = "Turner, {Barbara J.} and Daozhi Zhang and Christine Laine and Pomerantz, {Roger J.} and Leon Cosler and Hauck, {Walter W.}",
year = "2001",
month = "5",
day = "1",
language = "English (US)",
volume = "27",
pages = "20--29",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "0894-9255",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Association of provider and patient characteristics with HIV-infected women's antiretroviral therapy regimen

AU - Turner, Barbara J.

AU - Zhang, Daozhi

AU - Laine, Christine

AU - Pomerantz, Roger J.

AU - Cosler, Leon

AU - Hauck, Walter W.

PY - 2001/5/1

Y1 - 2001/5/1

N2 - Objective: We explored the effect of patient and provider factors on the type of antiretroviral regimen among women receiving therapy. Patients: Five hundred ninety-five New York State nonpregnant HIV + women with full Medicaid eligibility and at least 1 month of a prescribed antiretroviral regimen in federal fiscal years (FFY) 1997-1998 and intervals in FFY 1997-1998, who had delivered a liveborn baby within 5 years. Measurements: From pharmacy claims in 4 6-month intervals in FFY 1997-1998, data were extracted on (1) an acceptable ≥2 antiretroviral combination regimen per expert guidelines; and (2) a highly active regimen, including a protease inhibitor or nonnucleoside analog (highly active antiretroviral therapy [HAART]). Results: Of 1514 woman-6-month intervals with filled antiretroviral prescriptions, 82% had an acceptable regimen, and of 1246 woman-6-month intervals on acceptable antiretroviral therapy, half demonstrated the use of HAART. Adjusted odds ratios (AORs) of acceptable antiretroviral therapy were higher (p < .05) for HIV specialty care (AOR = 1.71 for one or two visits; AOR = 2.10 for 3+ visits) or HIV clinical trials site care (AOR = 1.43; 95% confidence interval [CI]: 1.01, 2.04). Among women on acceptable antiretroviral regimens, those aged older than 25 years (AOR = 1.69; CI: 1.13, 2.53) or who were high school graduates (AOR = 1.50; CI: 1.09, 2.06) had higher odds of HAART. Methadone-treated women had twofold and nearly three-fold higher AORs of acceptable antiretroviral regimens and HAART, respectively, than current drug users. Conclusion: Provider HIV expertise is associated with receipt of an acceptable antiretroviral regimen in women, although receipt of HAART is affected more by age, education, and current drug abuse. Methadone treatment seems to improve access to acceptable antiretroviral regimens as well as to HAART.

AB - Objective: We explored the effect of patient and provider factors on the type of antiretroviral regimen among women receiving therapy. Patients: Five hundred ninety-five New York State nonpregnant HIV + women with full Medicaid eligibility and at least 1 month of a prescribed antiretroviral regimen in federal fiscal years (FFY) 1997-1998 and intervals in FFY 1997-1998, who had delivered a liveborn baby within 5 years. Measurements: From pharmacy claims in 4 6-month intervals in FFY 1997-1998, data were extracted on (1) an acceptable ≥2 antiretroviral combination regimen per expert guidelines; and (2) a highly active regimen, including a protease inhibitor or nonnucleoside analog (highly active antiretroviral therapy [HAART]). Results: Of 1514 woman-6-month intervals with filled antiretroviral prescriptions, 82% had an acceptable regimen, and of 1246 woman-6-month intervals on acceptable antiretroviral therapy, half demonstrated the use of HAART. Adjusted odds ratios (AORs) of acceptable antiretroviral therapy were higher (p < .05) for HIV specialty care (AOR = 1.71 for one or two visits; AOR = 2.10 for 3+ visits) or HIV clinical trials site care (AOR = 1.43; 95% confidence interval [CI]: 1.01, 2.04). Among women on acceptable antiretroviral regimens, those aged older than 25 years (AOR = 1.69; CI: 1.13, 2.53) or who were high school graduates (AOR = 1.50; CI: 1.09, 2.06) had higher odds of HAART. Methadone-treated women had twofold and nearly three-fold higher AORs of acceptable antiretroviral regimens and HAART, respectively, than current drug users. Conclusion: Provider HIV expertise is associated with receipt of an acceptable antiretroviral regimen in women, although receipt of HAART is affected more by age, education, and current drug abuse. Methadone treatment seems to improve access to acceptable antiretroviral regimens as well as to HAART.

KW - Antiretroviral agents

KW - Physicians' practice patterns

KW - Practice guidelines

KW - Quality of health care

KW - Substance abuse

UR - http://www.scopus.com/inward/record.url?scp=0035330160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035330160&partnerID=8YFLogxK

M3 - Article

C2 - 11404516

AN - SCOPUS:0035330160

VL - 27

SP - 20

EP - 29

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 0894-9255

IS - 1

ER -